Please login to the form below

Not currently logged in

Boehringer teams up with Eureka on intracellular cancer targets

Alliance will use Eureka technology to identify antibodies recognising relevant proteins

Boehringer Ingelheim headquarters 

Boehringer Ingelheim and Eureka Therapeutics have joined forces in a collaboration to discover therapeutic antibodies for cancer.

The alliance will deploy Eureka's technology to identify antibodies recognising intracellular proteins, which represent around 90% of cancer-specific targets but have proved a challenge for conventional drug discovery techniques.

Currently, antibody-based therapies for cancer target proteins on the surface of cancer cells or in some cases extracellular targets, but they cannot readily cross cell membranes. Unfortunately, surface proteins account for only a fraction of potential tumour targets and are often not specific to cancers, leading to side effects. 

Eureka's platform will be used to identify peptide 'epitopes' that derive from intracellular proteins but are displayed on the cell surface via a process known as major histocompatibility complex (MHC) class I antigen presentation.

Boehringer said it would use the technology to develop better therapies for cancer patients, "for whom treatment options are inadequate or non-existent."

The agreement marks the continued expansion of Boehringer into oncology, a sector it has only been working on since 2006. The company's R&D efforts led to the approval of lung cancer therapy Giotrif (afatinib) in 2013, which was followed by a green light for another lung cancer therapy - Vargatef (nintedanib) - last year.

The Eureka collaboration "underlines our long-term commitment to oncology," commented Michel Pairet, vice president of research and non-clinical development at Boehringer, adding: "It will open up entirely new opportunities for the development of tumour cell- as well as immune cell-targeted therapies."

The financial details of the deal with Eureka have not been revealed, but the Californian biotech stands to receive an upfront technology access fee plus research funding for each programme. It could also be in line for technical success fees, option exercise fees, and other downstream payments.

Article by
Phil Taylor

22nd May 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...